Antidepressant Medications: 
Use in Adults

The Centers for Medicare & Medicaid Services (CMS) Medicaid Integrity Group (MIG) has identified issues with the utilization of the antidepressant drug therapy class. The U.S. Food and Drug Administration (FDA) approves product labeling for prescription drugs. The MIG has identified that some providers may have prescribed antidepressant medications outside of FDA-approved product labeling for indication, age, dosage, or duration of therapy. Therefore, CMS’ goal is to improve quality of care and enhance patient safety by educating providers on the proper use of antidepressants in adults.

This fact sheet summarizes the current FDA-approved product labeling for the use of antidepressant medications in adult patients. After reading this fact sheet, providers should be able to accurately:

• Identify the FDA-approved indications and dosages for the use of antidepressant medications in adults;
• Identify the available treatment guidelines for use of antidepressant medications in adults; and
• Summarize the adverse reactions and risks of antidepressant medications.

FDA-Approved Indications for Antidepressant Medications in Adults

According to a study by the Substance Abuse and Mental Health Services Administration (SAMHSA), the percentage of adults in the United States had a major depressive episode from 2005 to 2012 has been steady at about 6.5 percent to 7 percent. In 2012, women were 60 percent more likely to have reported a major depressive episode than men.[1] A survey by the Centers for Disease Control and Prevention (CDC) and the National Center for Health Statistics (NCHS) showed that antidepressant medications were the prescription medications most frequently used by adults 20 to 59 years old.[2]

Antidepressants are used in adults to treat depression, major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, panic disorder, social anxiety disorder, generalized anxiety disorder (GAD), posttraumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain, and seasonal affective disorder (SAD). They are also used for smoking cessation, insomnia, moderate to severe vasomotor symptoms associated with menopause, and as adjunct therapies for bipolar I disorder and Parkinson’s disease.

There are several different subclasses of antidepressants: selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Some antidepressants are prescribed exclusively for nonpsychiatric indications, such as insomnia, Parkinson’s disease, smoking cessation, and vasomotor symptoms of menopause, but these medications are not covered in this document. There are also other antidepressants that do not fall into any of these drug subclasses.
Refer to the dosing table in the document “Antidepressant Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults” available at https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/antidepressant-education.html on the CMS website for more information. FDA-approved indications vary by medication; therefore, a summary of the indications and the antidepressant(s) approved to treat each indication is provided in Table 1.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>bipolar I disorder</td>
<td>fluoxetine (Prozac®)[3]</td>
</tr>
<tr>
<td>bulimia nervosa</td>
<td>fluoxetine (Prozac)</td>
</tr>
<tr>
<td>chronic musculoskeletal pain</td>
<td>duloxetine[4]</td>
</tr>
<tr>
<td>diabetic peripheral neuropathy</td>
<td>duloxetine</td>
</tr>
<tr>
<td>fibromyalgia</td>
<td>duloxetine, milnacipran[18]</td>
</tr>
<tr>
<td>GAD</td>
<td>duloxetine, escitalopram,[19] paroxetine (Paxil®[20]; Pexeva®[21]), venlafaxine ER[22]</td>
</tr>
<tr>
<td>OCD</td>
<td>clomipramine,[40] fluoxetine (Prozac), fluvoxamine,[41] fluvoxamine ER,[42] paroxetine (Paxil; Pexeva), sertraline</td>
</tr>
<tr>
<td>panic disorder</td>
<td>fluoxetine (Prozac), paroxetine (Paxil; Pexeva), paroxetine CR, sertraline, venlafaxine ER</td>
</tr>
<tr>
<td>PMDD</td>
<td>fluoxetine (Sarafem®),[43] paroxetine CR, sertraline</td>
</tr>
<tr>
<td>PTSD</td>
<td>paroxetine (Paxil), sertraline</td>
</tr>
<tr>
<td>SAD</td>
<td>bupropion ER</td>
</tr>
<tr>
<td>social anxiety disorder</td>
<td>paroxetine (Paxil), paroxetine CR, sertraline, venlafaxine ER</td>
</tr>
</tbody>
</table>

CR = controlled-release      DR = delayed-release     ER = extended-release     SR = sustained-release
Treatment Guidelines for the Use of Antidepressant Medications in Adults

Information on some of the treatment guidelines for the use of antidepressants in adults is available in the National Guideline Clearinghouse database at https://www.guideline.gov on the Agency for Healthcare Research and Quality (AHRQ) website. The AHRQ is a branch of the U.S. Department of Health and Human Services. Links to some of the treatment guidelines for the use of antidepressants in adults are provided in Table 2.

Table 2. Treatment Guidelines for the Use of Antidepressant Medications in Adults

<table>
<thead>
<tr>
<th>Sponsoring Organization</th>
<th>Title of Guideline</th>
<th>Link to Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institute for Clinical Systems Improvement</td>
<td>Adult depression in primary care. [2013]</td>
<td><a href="https://www.guideline.gov/content.aspx?id=47315">https://www.guideline.gov/content.aspx?id=47315</a></td>
</tr>
</tbody>
</table>

Adverse Reactions and Risks of Antidepressant Medications

Adverse reactions vary for each antidepressant drug subclass. SSRIs and SNRIs are the most frequently used antidepressants because they tend to have less bothersome adverse reactions than most of the other antidepressants. The most common adverse reactions of SSRIs and SNRIs are headache, nausea, sedation, agitation, and sexual problems. Hyponatremia has been reported with SSRIs and SNRIs, which may be secondary to drug-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH). Symptoms of SIADH are confusion, weakness, difficulty concentrating, and memory impairment. Patients who develop hyponatremia should have appropriate medical intervention, and discontinuation of the SSRI or SNRI should be considered.[44]

TCAs have anticholinergic properties that cause many troublesome adverse reactions, such as dry mouth, constipation, urinary retention, and blurred vision. Drowsiness is the most common side effect and usually subsides as therapy continues. TCAs should be used with caution in patients with a heart condition. A TCA overdose may be lethal.[45]

The use of MAOIs is limited because they have several contraindications which include:

- Presence of a cerebrovascular defect;
- Presence of a cardiovascular disorder;
- Presence of a pheochromocytoma;
- Consumption of tyramine-containing foods; and
- Potential for serious drug interactions with some medications.[46]
MAOIs also have a warning that they may cause a potentially fatal hypertensive crisis when tyramine-containing foods are consumed.[47] Information on tyramine-containing foods can be found at http://clinicalcenter.nih.gov/ccc/patient_education/drug_nutrient/maoi1.pdf on the National Institutes of Health (NIH) website.

More detailed information on adverse reactions, drug interactions, warnings, contraindications, and precautions can be found in the prescribing information for each medication. Links are available by searching for the individual medication at https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm on the FDA website or by searching the endnotes of this fact sheet for the respective drugs.

**Risk of Suicidality**

Antidepressant medications have been shown to increase the risk of suicidal thinking and behavior. In pooled analyses of short-term, placebo-controlled trials of nine antidepressant medications, patients taking an antidepressant had twice the risk of suicidality in the first few months of treatment as those taking placebo. The long-term risk is unknown. As a result of these analyses, and since the risk was not confined to one subclass of antidepressants, a boxed warning was added to all antidepressant medications.[48]

The boxed warning for all antidepressant medications states:[49]

**SUICIDALITY AND ANTIDEPRESSANT DRUGS**

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of [Insert established name] or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. [Insert Drug Name] is not approved for use in pediatric patients. [The previous sentence would be replaced with the sentence, below, for the following drugs: Prozac: Prozac is approved for use in pediatric patients with MDD and obsessive compulsive disorder (OCD). Zoloft: Zoloft is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD). Fluvoxamine: Fluvoxamine is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD).] (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use)
The FDA also requires that a Medication Guide be dispensed with every antidepressant prescription to alert patients and caregivers to the risk of suicidal thinking and behavior. It also includes information on precautions that may be taken.[50] The risks associated with antidepressant use in adults must be weighed against the potential benefits.

**Risk of Angle-Closure Glaucoma**

In July 2014, the FDA released a new warning about the link between antidepressant drugs and angle-closure glaucoma. Dilation of the pupil after taking an antidepressant may trigger an angle closure attack in people with anatomically narrow angles who have not had a patent iridectomy. Symptoms may include eye pain, changes in vision, or swelling or redness in or around the eye. Patients may wish to be examined for susceptibility to angle-closure glaucoma to determine if a preventive iridectomy is indicated.[51]

**Risk of Hypertension**

Venlafaxine and desvenlafaxine have been shown to cause sustained hypertension. The increase in blood pressure appears to be dose related. Patients with preexisting hypertension should have their blood pressure controlled prior to initiation of therapy with venlafaxine or desvenlafaxine, and should be routinely monitored throughout treatment. If a patient experiences an increase in blood pressure, the dose should be decreased or the medication should be discontinued.[52, 53]

**Risk of Serotonin Syndrome**

Patients taking SSRIs or SNRIs are at risk for serotonin syndrome when combined with another serotonergic medication. Other medications that are known to increase the risk for serotonin syndrome are the triptans, linezolid, and methylene blue. Symptoms of serotonin syndrome are highly variable, but can include hyperthermia, hypertension, hallucinations, confusion, weakness, dizziness, and ataxia. The risk of concomitant treatment should be weighed against the potential benefits. If it is determined that a patient needs to be treated with both medications, close monitoring is recommended. Patients and caregivers should also be made aware of the risk of serotonin syndrome and its signs and symptoms.[54, 55]
Risk of Hepatotoxicity

There have been reports of hepatotoxicity in patients taking duloxetine. Cases of liver failure have also been reported. Duloxetine should be discontinued if jaundice develops or if there are other indications of liver dysfunction. Patients with evidence of liver disease or who consume significant amounts of alcohol should not be prescribed duloxetine.[56]

Life-threatening liver failure has been reported with nefazodone. A boxed warning has been added to alert patients and providers to this risk.

The boxed warning for nefazodone states:[57]

**WARNING**

Cases of life-threatening hepatic failure have been reported in patients treated with nefazodone hydrochloride tablets. The reported rate in the United States is about 1 case of liver failure resulting in death or transplant per 250,000 to 300,000 patient-years of nefazodone hydrochloride treatment. The total patient-years is a summation of each patient’s duration of exposure expressed in years. For example, 1 patient-year is equal to 2 patients each treated for 6 months, 3 patients each treated for 4 months, etc. (see WARNINGS).

Ordinarily, treatment with nefazodone hydrochloride tablets should not be initiated in individuals with active liver disease or with elevated baseline serum transaminases. There is no evidence that pre-existing liver disease increases the likelihood of developing liver failure, however, baseline abnormalities can complicate patient monitoring.

Patients should be advised to be alert for signs and symptoms of liver dysfunction (jaundice, anorexia, gastrointestinal complaints, malaise, etc.) and to report them to their doctor immediately if they occur.

Nefazodone hydrochloride tablets should be discontinued if clinical signs or symptoms suggest liver failure (see PRECAUTIONS, Information for Patients). Patients who develop evidence of hepatocellular injury such as increased serum AST or serum ALT levels ≥ 3 times the upper limit of NORMAL, while on nefazodone hydrochloride treatment should be withdrawn from the drug. These patients should be presumed to be at increased risk for liver injury if nefazodone hydrochloride is re-introduced. Accordingly, such patients should not be considered for re-treatment.

Risk of Seizures

Bupropion has been associated with seizures. The risk for seizures appears to be dose related, but is also related to patient factors, clinical condition, and concomitant medications. If a patient experiences a seizure while taking bupropion, the medication should be discontinued and should not be restarted.[58]

Seizures were reported during premarket evaluation of clomipramine. The risk of seizures was related to the dose of clomipramine, the duration of treatment, or both factors. Caution should be used when prescribing clomipramine to patients with a history of seizures or other factors that may predispose them to seizures.[59]

Maprotiline has been associated with seizures, especially in patients with a known seizure disorder. However, rapid increases in dose, concurrent administration with medications that lower the seizure threshold, and dosages that exceed the therapeutic range have also been associated with seizures. The prescribing information recommends initiating maprotiline at a low dosage, maintaining the initial dose for at least 2 weeks, increasing the dose in small increments, and maintaining maprotiline at the lowest effective dosage.[60]

Seizures have been associated with other antidepressant medications. SSRIs, SNRIs, TCAs, mirtazapine, nefazodone, and vilazodone warn that they should be used with care when antidepressant therapy is initiated in a patient with a known seizure disorder.

Antidepressant Medications: Use in Adults

6
Risk of Neuropsychiatric Events with Bupropion

Bupropion has been reported to cause neuropsychiatric events when used for smoking cessation. Symptoms associated with these events include behavioral changes, agitation, depression, hostility, and suicidality. Patients and caregivers should be instructed to discontinue bupropion and to contact a healthcare provider if any of these symptoms occur. Bupropion has also been reported to worsen preexisting psychiatric illness in patients who were taking it to stop smoking.[61]

Although bupropion products other than Zyban® do not have FDA approval for smoking cessation, they all have a boxed warning to alert providers, patients, and caregivers to the risk of neuropsychiatric events when used for smoking cessation.[62, 63, 64]

The boxed warning for Wellbutrin® states:[65]

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; AND NEUROPSYCHIATRIC REACTIONS

SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older [see Warnings and Precautions (5.1)].

In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1)].

NEUROPSYCHIATRIC REACTIONS IN PATIENTS TAKING BUPROPION FOR SMOKING CESSION

Serious neuropsychiatric reactions have occurred in patients taking bupropion for smoking cessation [see Warnings and Precautions (5.2)]. The majority of these reactions occurred during bupropion treatment, but some occurred in the context of discontinuing treatment. In many cases, a causal relationship to bupropion treatment is not certain, because depressed mood may be a symptom of nicotine withdrawal. However, some of the cases occurred in patients taking bupropion who continued to smoke. Although WELLBUTRIN® is not approved for smoking cessation, observe all patients for neuropsychiatric reactions. Instruct the patient to contact a healthcare provider if such reactions occur [see Warnings and Precautions (5.2)].

Risk of Cardiac Arrhythmias with Fluoxetine and Citalopram

Two recent FDA Drug Safety Communications have been published to notify patients and healthcare providers about the potential risk of abnormal heart rhythms with fluoxetine and with high doses of citalopram. Citalopram has been shown to cause prolongation of the QT interval,[66] and fluoxetine has been associated with reports of postmarketing cases of QT prolongation.[67] Patients with underlying heart conditions, hypokalemia, or hypomagnesemia are at risk of developing prolongation of the QT interval, which may lead to Torsade de Pointes. Fluoxetine and citalopram are not recommended for use in patients who are taking another medication that can prolong the QT interval. The use of citalopram is not recommended in patients who have had a recent myocardial infarction or who have uncompensated heart failure, congenital long QT syndrome, bradycardia, hypokalemia, or hypomagnesemia.[68] Fluoxetine should be used with caution in these patients. Additionally, fluoxetine should be used with caution in patients with conditions that may predispose them to increased fluoxetine exposure such as overdose, hepatic impairment, CYP2D6 poor metabolizer status, and concurrent use of CYP2D6 inhibitors or other highly protein-bound drugs.[69]
Resources

Visit http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-State/By-State.html for links to State Medicaid program websites.

The FDA requires that a Medication Guide be issued with some medications to provide information to patients on serious adverse reactions and how to avoid them. Links to the required Medication Guides can be found at http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm on the FDA website.

The Center for Drug Evaluation and Research (CDER) hosts a website providing health professionals with current information on over-the-counter (OTC) and prescription drugs. Visit http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals to access drug-related databases, information on drug recalls and alerts, current information on new and generic drug approvals, and information on drug safety and availability.

Section 1927(g)(1)(B) of the Social Security Act identifies the predetermined standards that the State’s drug use review program must use to assess data on drug use. Visit http://www.ssa.gov/OP_Home/ssact/title19/1927.htm for information on the compendia.

To see the electronic version of this fact sheet and the other products included in the “Antidepressants” Toolkit, visit the Medicaid Program Integrity Education page at https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/pharmacy-ed-materials.html on the CMS website.

Follow us on Twitter #MedicaidIntegrity

References


Antidepressant Medications: Use in Adults

Antidepressant Medications: Use in Adults


Antidepressant Medications: Use in Adults


Antidepressant Medications: Use in Adults

Disclaimer

This fact sheet was current at the time it was published or uploaded onto the web. Medicaid and Medicare policies change frequently so links to the source documents have been provided within the document for your reference.

This fact sheet was prepared as a service to the public and is not intended to grant rights or impose obligations. This fact sheet may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. Use of this material is voluntary. Inclusion of a link does not constitute CMS endorsement of the material. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.

October 2015

This fact sheet was prepared by the Education Medicaid Integrity Contractor for the CMS Medicaid Program Integrity Education (MPIE). For more information on the MPIE, visit https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/pharmacy-ed-materials.html on the CMS website or scan the Quick Response (QR) code on the right with your mobile device.